Inventia Healthcare has pulled more than 25,000 bottles of its 25-milligram chlorthalidone tablets — a generic blood pressure and fluid-retention medication — after testing found the pills failed to dissolve at the rate the FDA requires.
Why dissolution matters
Dissolution testing measures how quickly a tablet breaks down so the body can absorb its active ingredient. When a drug fails dissolution specifications, as the FDA describes these batches, it means the medicine may not be absorbed as intended — potentially making it less effective at controlling blood pressure or excess fluid, even though the pills are not considered contaminated or mislabeled.
Scope of the recall
- 11,460 bottles recalled in June 2026
- 13,567 bottles recalled in September 2026, including batch RISA24002 (NDC 64980-599-01), expiring April 2027
- FDA recall numbers D-0610-2026 and D-0852-2026
- Classified Class II: a risk of temporary or reversible health effects, with a remote chance of serious harm
What patients should do
Patients taking chlorthalidone should check their pill bottle's lot number against the recalled batches and talk to their pharmacist or prescriber before stopping or switching medication on their own — abruptly discontinuing a blood pressure drug carries its own risks. No injuries have been reported in connection with the recall.
